Aktienanalyse zu IDEAYA Biosciences Inc (IDYA)IDYAIDEAYA Biosciences Inc

IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

IDEAYA Biosciences Inc appears to be a good buy right now, with a current price of $40.11 and a forward P/E ratio of 4.649, indicating potential for growth. The stock has shown a remarkable 1-year change of +57.42%, reflecting strong upward momentum. Additionally, the RSI is at 53.462, suggesting that the stock is neither overbought nor oversold, which is favorable for new investors. However, the main risk is the negative net income reported for the last quarter at -112,452,000 USD, which highlights ongoing financial challenges that could impact future performance.